Neurology · Foxborough, MA
Neurology studies in Foxborough, MA
10 recruiting studies have a site in Foxborough.
10 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
TG Therapeutics, Inc.
- Location
- Foxborough, MA + 35 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2/Phase 3
A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
Biohaven Therapeutics Ltd.
- Location
- Foxborough, MA + 24 other US sites
- Eligibility basics
- Ages 40–80
- RecruitingPhase 3
A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
Kallyope Inc.
- Location
- Foxborough, MA + 35 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Novartis Pharmaceuticals
- Location
- Foxborough, MA + 42 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
Sanofi
- Location
- Foxborough, MA + 33 other US sites
- Eligibility basics
- Ages 18–60
- RecruitingPhase 2
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
Eli Lilly and Company
- Location
- Foxborough, MA + 29 other US sites
- Eligibility basics
- Ages 55–85
- RecruitingPhase 2
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
Celgene
- Location
- Foxborough, MA + 31 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 2
Study of EVO756 in Adults With Migraine
Evommune, Inc.
- Location
- Foxborough, MA + 32 other US sites
- Eligibility basics
- Ages 18–64
- RecruitingPhase 2
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
Celgene
- Location
- Foxborough, MA + 13 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
Novartis Pharmaceuticals
- Location
- Foxborough, MA + 42 other US sites
- Eligibility basics
- Ages 40–70
Who these studies look for
Most require a confirmed diagnosis; memory studies often ask for a study partner who knows you well to attend some visits.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.